Veltio Pharma AB

Veltio Pharma is a Swedish biotechnology company based in Uppsala that specializes in enhancing the bioavailability of poorly soluble drugs. The company utilizes a proprietary nanotechnology platform based on renewable, biodegradable porous algae cellulose to transform poorly soluble active pharmaceutical ingredients (APIs) into effective solid oral dosage forms. The company focuses on de-risking drug development by improving the pharmacokinetic profiles of drug candidates, particularly in therapeutic areas such as pain, inflammation, immune disorders, and oncology. Veltio Pharma operates as a service provider and licensing partner, supporting preclinical to Phase I/IIa development stages with a strong emphasis on sustainable, eco-friendly manufacturing processes.